Aidsmap: "The latest data from a European trial using boosted darunavir (DRV/r) as the sole HIV drug has found no evidence of increased treatment failure or of viral loads increasing over time, even when viral loads below the usual limit of detectability were investigated with an ultrasensitive assay.
"The latest results from the MONET trial, presented at the recent Tenth Congress on Drug Therapy in HIV Infection, contrast with an African trial using boosted lopinavir monotherapy (LPV/r) also presented which, in the absence of viral load testing, found increased rates of viral failure over time."
0 comments:
Post a Comment